Lipella pharmaceuticals to participate at h.c. wainwright's 26th annual global investment conference in new york

Company has two lead drug candidates for rare disease indications in ind approved phase 2 clinical trials using the 505(b)(2) pathway pittsburgh, pa, august 27, 2024 – lipella pharmaceuticals, inc. (nasdaq: lipo) (“lipella”) will participate at h.c.
LIPO Ratings Summary
LIPO Quant Ranking